Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CPIX Stock Forecast 2026-2027
$5.60
Current Price
$83.91M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CPIX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CPIX Price Momentum
-4.4%
1 Week Change
+2.4%
1 Month Change
+6.9%
1 Year Change
+40.7%
Year-to-Date Change
-15.3%
From 52W High of $6.61
+202.7%
From 52W Low of $1.85
📊 TOP ANALYST CALLS
Did CPIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cumberland Pharmaceuticals is one of their latest high-conviction picks.
Latest CPIX Stock Price Targets & Analyst Predictions
CPIX has shown a year-to-date change of 40.7% and a 1-year change of 6.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CPIX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CPIX Analyst Ratings
0
Buy
1
Hold
0
Sell
CPIX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $5.60
Latest CPIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CPIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2019 | B. Riley | Buy | Maintains | $N/A | |
| Dec 3, 2019 | B. Riley Securities | Andrew D'Silva | Buy | Maintains | $9.75 |
| Nov 18, 2019 | B. Riley FBR | Buy | Maintains | $N/A | |
| Nov 18, 2019 | B. Riley Securities | Buy | Maintains | $N/A | |
| Aug 17, 2018 | B. Riley FBR | Buy | Maintains | $N/A | |
| Aug 17, 2018 | B. Riley Securities | Buy | Maintains | $N/A | |
| May 5, 2018 | B. Riley FBR | Buy | Initiates | $N/A | |
| Apr 17, 2018 | B. Riley FBR | Buy | Initiates | $N/A | |
| Apr 17, 2018 | B. Riley Securities | Buy | Initiates | $N/A | |
| Apr 10, 2013 | UBS | Neutral | Maintains | $N/A | |
| Nov 12, 2012 | UBS | Neutral | Maintains | $N/A | |
| Nov 9, 2012 | Wells Fargo | Market Perform | Downgrade | $N/A |
Cumberland Pharmaceuticals Inc. (CPIX) Competitors
The following stocks are similar to Cumberland Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CPIX
Cumberland Pharmaceuticals
mkt cap
83.91M
Cumberland Pharmaceuticals Inc. (CPIX) Financial Data
Cumberland Pharmaceuticals Inc. has a market capitalization of $83.91M with a P/E ratio of -29.3x. The company generates $41.94M in trailing twelve-month revenue with a -17.6% profit margin.
Revenue growth is -22.0% quarter-over-quarter, while maintaining an operating margin of -34.3% and return on equity of -29.8%.
Valuation Metrics
Market Cap
$83.91M
Enterprise Value
$82.63M
P/E Ratio
-29.3x
PEG Ratio
0.1x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
-22.0%
Gross Margin
+78.8%
Operating Margin
-34.3%
Net Margin
-17.6%
EPS Growth
-22.0%
Financial Health
Cash/Price Ratio
+13.1%
Current Ratio
1.0x
Debt/Equity
47.3x
ROE
-29.8%
ROA
-6.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cumberland Pharmaceuticals Inc. (CPIX) Business Model
About Cumberland Pharmaceuticals Inc.
What They Do
Develops innovative prescription products for healthcare.
Business Model
Cumberland Pharmaceuticals generates revenue by developing and commercializing niche-market prescription products that fulfill specific medical needs. The company utilizes a direct salesforce and partnerships with healthcare providers and distributors to maximize product availability in the U.S. market.
Additional Information
Founded in 1999 and based in Nashville, Tennessee, Cumberland focuses on areas such as hospital acute care, gastroenterology, and oncology. Its commitment to addressing unmet medical needs positions it as a crucial player in the pharmaceutical industry, enhancing treatment outcomes for patients.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
93
CEO
Mr. A. J. Kazimi MBA
Country
United States
IPO Year
2009
Website
www.cumberlandpharma.comCumberland Pharmaceuticals Inc. (CPIX) Latest News & Analysis
Latest News
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
6 days ago
Quick Summary
RedHill Biopharma Ltd. announced news from Raleigh, N.C., and Tel-Aviv, Israel, on June 8, 2026. Further details were not provided in the excerpt.
Why It Matters
RedHill Biopharma's developments could impact stock performance, signaling potential growth or risk in biopharma investments, influencing investor sentiment and market positioning.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has granted opaganib rare pediatric disease designation for neuroblastoma, offering benefits like a Priority Review Voucher and potential market exclusivity. The neuroblastoma market may reach $3.5 billion by 2032.
Why It Matters
The FDA's designation for opaganib enhances its market potential, offering accelerated approval and exclusivity. The neuroblastoma market's growth to $3.5 billion presents significant investment opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CPIX announced positive Phase 2a results for Ifetroban, indicating a favorable safety profile and early signs of effectiveness in reducing cancer metastasis in high-risk patients.
Why It Matters
CPIX’s positive Phase 2a results for Ifetroban indicate potential market growth and future revenue, boosting investor confidence in the company's prospects and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
12 days ago
Quick Summary
Cumberland Pharmaceuticals' Phase 2a trial of ifetroban showed safety and efficacy in high-risk solid tumors, with fewer metastasis-related deaths compared to placebo (p=0.037).
Why It Matters
Positive Phase 2a results for ifetroban suggest potential market value and advancements in cancer treatment, boosting Cumberland Pharmaceuticals' growth prospects and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CPIX has launched its antibiotic Vibativ in China via SciClone, enhancing access to treatment for serious Gram-positive bacterial infections.
Why It Matters
CPIX's launch of Vibativ in China signifies potential revenue growth and market expansion, enhancing its position in the antibiotic sector and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
RedHill Biopharma is exploring collaborations to advance opaganib for Ebola amid an outbreak of the Bundibugyo ebolavirus. Phase 3 data shows a 70.2% mortality reduction in severe COVID-19 cases.
Why It Matters
RedHill Biopharma's collaboration on opaganib for Ebola could position the company favorably in the biopharma market, potentially boosting stock value and attracting investor interest due to promising efficacy data.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CPIX Stock
What is Cumberland Pharmaceuticals Inc.'s (CPIX) stock forecast for 2026?
Analyst forecasts for Cumberland Pharmaceuticals Inc. (CPIX) are not currently available. The stock is trading at $5.60.
Is CPIX stock a good investment in 2026?
According to current analyst ratings, CPIX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CPIX stock?
Price predictions from Wall Street analysts for CPIX are not currently available. The stock is trading at $5.60.
What is Cumberland Pharmaceuticals Inc.'s business model?
Cumberland Pharmaceuticals generates revenue by developing and commercializing niche-market prescription products that fulfill specific medical needs. The company utilizes a direct salesforce and partnerships with healthcare providers and distributors to maximize product availability in the U.S. market.
What is the highest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $5.60.
What is the lowest forecasted price for CPIX Cumberland Pharmaceuticals Inc.?
Price targets from Wall Street analysts for CPIX are not currently available. The stock is trading at $5.60.
What is the overall CPIX consensus from analysts for Cumberland Pharmaceuticals Inc.?
The overall analyst consensus for CPIX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CPIX stock price projections?
Stock price projections, including those for Cumberland Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 2:34 AM UTC